Puma Biotechnology Cash Flow Statement
NASDAQ: PBYIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Puma Biotechnology free cash flow
In fiscal 2025, Puma Biotechnology generated $41.8 million of operating cash flow and spent $71,000 on capital expenditures. That left free cash flow of $41.7 million, a free-cash-flow margin of 18.3% of revenue. Free cash flow was up 7.4% from the prior year's $38.9 million.
Summary generated from market data by MetaCap's automated system. Methodology
Puma Biotechnology cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 31.11M | 30.28M | 21.59M | 2.00K | -29.13M | -59.99M | -75.59M | -113.58M | -291.95M | -276.01M |
| Net Income growth (YoY) | +2.75% | +40.23% | +1079450.00% | — | — | — | — | — | — | — |
| Depreciation & Amortization | 10.94M | 11.52M | 11.52M | 9.84M | 11.30M | 10.03M | 8.08M | 7.38M | 2.81M | 1.15M |
| Stock-Based Compensation | 6.94M | 8.24M | 10.25M | 11.83M | 32.63M | 36.58M | 57.33M | 86.94M | 108.73M | 117.26M |
| Change in Working Capital | -18.52M | 13.32M | -10.47M | -9.97M | -10.54M | -5.04M | 12.40M | -2.92M | 9.18M | 5.02M |
| Operating Cash Flow | 41.80M | 38.92M | 27.01M | -15.83M | 20.65M | 773.00K | 22.38M | -24.11M | -172.47M | -141.69M |
| Capital Expenditures | -71.00K | -56.00K | -140.00K | 0 | 0 | -46.00K | -306.00K | -439.00K | -431.00K | -4.29M |
| Investing Cash Flow | -36.19M | -20.44M | -19.13M | 7.10M | -10.88M | 33.40M | 5.16M | -57.62M | -15.44M | 142.19M |
| Debt Issued | — | — | 0 | 0 | 98.50M | 8.44M | 25.00M | 105.00M | 50.00M | — |
| Debt Repaid | -44.44M | -33.33M | 0 | 0 | -100.00M | -8.44M | -80.00M | — | — | — |
| Financing Cash Flow | -45.20M | -33.85M | 0 | 12.22M | -31.93M | -9.93M | -67.07M | 108.45M | 75.11M | 162.43M |
| Net Change in Cash | -39.58M | -15.37M | 7.88M | 3.50M | -22.16M | 24.24M | -39.53M | 26.72M | -112.80M | 162.93M |
| Free Cash Flow | 41.73M | 38.86M | 26.87M | -15.83M | 20.65M | 727.00K | 22.07M | -24.54M | -172.90M | -145.98M |
This table shows 10 annual periods of Puma Biotechnology's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PBYI's reporting calendar. What is a cash flow statement?